Thermo Fisher Scientific (NYSE:TMO) announced on Monday that it has entered into a definitive agreement to sell its microbiology business to Astorg, a prominent pan-European private equity firm.
The transaction is valued at approximately $1.075 billion, comprised of a cash payment and a $50 million seller note.
The microbiology unit, which operates within Thermo Fisher’s Specialty Diagnostics segment, is a leading provider of culture media solutions and antimicrobial susceptibility testing.
These products are essential for clinical diagnostics, pharmaceutical quality control, and food safety testing.
In 2025, the business generated approximately $645 million in revenue, reflecting its significant role in the global laboratory supply chain.
Thermo Fisher expects the divestiture to be dilutive to adjusted earnings per share by approximately $0.15 in the first full year following the completion of the sale.
The deal is slated to close in the second half of 2026, contingent upon regulatory approvals and customary closing conditions.